Clinical trial

Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma

NCT00006216

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention PA-1-STK ovarian carcinoma vaccine Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record ganciclovir Normalized identity: ganciclovirView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date1997-08-01

PhasePHASE1

Conditions

Malignant Mesotheliomaverified · MONDO: malignant mesothelioma

Interventions

PA-1-STK ovarian carcinoma vaccineBIOLOGICAL

ganciclovirDRUG · verified · RxNorm: ganciclovir

Sponsors & collaborators

Louisiana State University Health Sciences Center in New Orleanslead sponsor

Mapped research locations

New OrleansLouisiana, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00006216 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.